Inavir

Type: Product

Name: Inavir

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Phase II

Biota Pharmaceuticals Reports Second Quarter Financial Results and Corporate Update

(GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced its financial results for the three month period ended March 31, 2013, and provided an update on recent corporate developments.In connection with announcing ... [Published GlobeNewswire - May 10 2013]

Entities: Laninamivir, Biota Pharmaceuticals Inc, Inavir, Daiichi Sankyo Co Ltd, Phase II

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Adolor Corporation

Biota Pharmaceuticals Announces Changes to Its Board of Directors

(GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company"), a biopharmaceutical company focused on the discovery and development of anti-infective products to prevent and treat serious and potentially life-threatening infectious ... [Published Morningstar.com - May 06 2013]

Entities: Biota Pharmaceuticals Inc, Adolor Corporation, Laninamivir

First reported Apr 16 2013 - Updated Apr 16 2013 - 1 reports

Biota Pharmaceuticals to Shake Things Up and Relocate HQ to Atlanta, Cutting 30 Pct of Staff

(GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) today announced that its Board of Directors has adopted a revised corporate strategy following the recent completion of management's strategic and operational review of the organization and ... [Published FierceBiotech - Apr 16 2013]

Entities: Laninamivir, Biota Pharmaceuticals Inc, Vapendavir

First reported Apr 15 2013 - Updated Apr 15 2013 - 1 reports

Daiichi Sankyo Co Ltd

Biota Pharmaceuticals Announces Results of Strategic and Operational Review

Entities: Biota Pharmaceuticals Inc, Laninamivir, Daiichi Sankyo Co Ltd, Inavir

Quotes

...including its simple, inhaled single dose treatment regimen," said Russell H Plumb, President and Chief Executive Officer of Biota Pharmaceuticals. "We look forward to initiating our Phase 2 trial of laninamivir octanoate this quarter." Board of Director Appointments ? On May 6, 2013 the Company announced a number of changes to its Board of Directors, including the resignations of both...

Biota Pharmaceuticals Reports Second Quarter Financial Results and Corporate Update [Published GlobeNewswire - May 10 2013]

"On behalf of Biota, I want to thank Raafat and Paul for their significant contributions toward creating the new Biota Pharmaceuticals and positioning it for future growth" said Dr. James Fox, Chairman of Biota PharmaceuticalsBiota Pharmaceuticals Inc.$ Ms...

Biota Pharmaceuticals Announces Changes to Its Board of Directors [Published Morningstar.com - May 06 2013]

...inical-stage development programs," stated Russell H Plumb, President and Chief Executive Officer of Biota PharmaceuticalsBiota Pharmaceuticals Inc. "This strategy is designed to streamline our portfolio of preclinical programs, conserve capital, and focus our operations on advancing or securing development programs that we believe can best drive shareholder value over the next several years."

Biota Pharmaceuticals to Shake Things Up and Relocate HQ to Atlanta, Cutting 30 Pct of Staff [Published FierceBiotech - Apr 16 2013]

...Peter Cook said approval in the new indication will expand the market applicability for Inavir and further solidify its role in pandemic control. "We continue to believe that Inavir's demonstrated efficacy, combined with its ease of use, have the opportunity to significantly improve clinical outcomes for the treatment and now prevention, of influenza" Cook added...

Biota Inavir meets primary endpoint in Phase III study [Published Pharmaceutical Business Review - Aug 23 2012]